Bio-Techne (TECH) president converts 4,621 RSUs and withholds shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Bio-Techne Corp President – Diag & Spatial Bio, Matthew McManus, reported equity award activity in company stock. On February 1, 2026, 4,621 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 1,665 common shares were withheld at $64.09 per share to cover obligations, leaving 7,691 common shares held directly.
McManus continues to hold multiple equity awards, including performance restricted stock units and stock options that vest over several future dates and run through expiration dates up to August 15, 2035. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
4,621 shares exercised/converted
Mixed
12 txns
Insider
McManus Matthew
Role
President - Diag & Spatial Bio
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 4,621 | $0.00 | -- |
| Exercise | Common Stock | 4,621 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,665 | $64.09 | $107K |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 4,620 shares (Direct);
Common Stock — 9,356 shares (Direct);
Performance Restricted Stock Units — 2,888 shares (Direct);
Performance Stock Option (Right to Buy) — 7,951 shares (Direct);
Stock Option (Right to Buy) — 15,902 shares (Direct)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027. Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 2,637 restricted stock units vest on 8/15/2026 and 2,638 restricted stock units vest on 8/15/2027. Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028. Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028.
FAQ
What insider activity did TECH executive Matthew McManus report on this Form 4?
Matthew McManus reported equity award activity involving Bio-Techne (TECH) shares. 4,621 restricted stock units converted into 4,621 common shares at $0 per share, and 1,665 common shares were withheld at $64.09 per share, leaving 7,691 common shares owned directly.
What happened to the 4,621 restricted stock units reported for Bio-Techne (TECH)?
The 4,621 restricted stock units converted into 4,621 Bio-Techne common shares at $0 per share. These units were part of an equity award, with each unit representing a contingent right to receive one common share, as described in the footnotes to the filing.
What derivative equity awards in TECH does Matthew McManus continue to hold?
Matthew McManus continues to hold various derivative awards in Bio-Techne, including performance restricted stock units and stock options. These awards cover tens of thousands of underlying shares and vest on multiple dates extending to August 15, 2035, according to the vesting schedules in the footnotes.
How do restricted stock units work in the Bio-Techne (TECH) Form 4 filing?
Each restricted stock unit in this Bio-Techne filing represents a contingent right to receive one common share. Units typically vest on specified future dates or upon meeting performance goals, and upon vesting they convert into common shares as shown by the 4,621-unit conversion.